Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Chronic Convection Enhanced Delivery of Topotecan

NCT: NCT03154996 · COMPLETED

NCT IDNCT03154996
StatusCOMPLETED
Start Date2018-01-18
Completion2021-08-20

Brief Summary

The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).

Frequently Asked Questions

What is Chronic Convection Enhanced Delivery of Topotecan?

Chronic Convection Enhanced Delivery of Topotecan is a clinical trial registered under NCT03154996. Current status: COMPLETED.

What is the status of NCT03154996?

The current status of NCT03154996 (Chronic Convection Enhanced Delivery of Topotecan) is: COMPLETED.

When did Chronic Convection Enhanced Delivery of Topotecan start?

Chronic Convection Enhanced Delivery of Topotecan started on 2018-01-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.